Victoza
| Dosaggio del prodotto: 6mg | |||
|---|---|---|---|
| Confezione (n.) | Per iniettore | Prezzo | Acquista |
| 1 | €384.66 | €384.66 (0%) | 🛒 Aggiungi al carrello |
| 2 | €363.29
Migliore per iniettore | €769.33 €726.59 (6%) | 🛒 Aggiungi al carrello |
Sinonimi | |||
Prodotti simili
Victoza is not a dietary supplement or a medical device in the traditional over-the-counter sense. It is a prescription medication, specifically a glucagon-like peptide-1 (GLP-1) receptor agonist, approved for the treatment of type 2 diabetes and, in some regions, for chronic weight management. The following monograph is structured to provide a comprehensive, evidence-based overview for healthcare professionals and informed patients, adhering to the requested format while accurately reflecting the nature of this pharmaceutical product.
1. Introduction: What is Victoza? Its Role in Modern Diabetes Management
LSI Keywords: What is Victoza, what is Victoza used for, benefits of Victoza, liraglutide injection, GLP-1 agonist.
Victoza (liraglutide) is a prescription medication belonging to the class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. It is administered via a subcutaneous injection, typically once daily. As a cornerstone of modern type 2 diabetes mellitus (T2DM) therapy, Victoza functions not merely as a glucose-lowering agent but as a disease-modifying treatment that addresses multiple pathophysiological defects of T2DM. Its significance lies in its proven efficacy for glycemic control, its associated weight loss benefit, and, crucially, its demonstrated cardiovascular outcome benefits in high-risk patients, which has fundamentally shifted its position in treatment algorithms from a later-line option to a preferred agent for many with established cardiovascular disease.
2. Key Component and Pharmacokinetics of Victoza
LSI Keywords: Composition of Victoza, liraglutide structure, release form, pharmacokinetics, half-life.
The active component of Victoza is liraglutide, a synthetic analog of human GLP-1. Its molecular structure is modified (97% homology to native GLP-1) with a fatty acid side chain, which allows it to bind reversibly to albumin in the bloodstream. This key modification confers a prolonged half-life of approximately 13 hours, enabling once-daily administration, unlike native GLP-1 which is degraded within minutes. Victoza is available as a clear, colorless solution in pre-filled multi-dose pens (6 mg/mL). The bioavailability of subcutaneous liraglutide is high (approximately 55%), and it reaches maximum concentration in 8-12 hours. Its pharmacokinetic profile supports steady-state concentrations with daily dosing, providing continuous GLP-1 receptor activation.
3. Mechanism of Action of Victoza: Scientific Substantiation
LSI Keywords: how Victoza works, mechanism of action of liraglutide, effects on pancreas, incretin effect, scientific research.
Victoza mimics the action of the endogenous incretin hormone GLP-1. Its effects are multi-factorial and glucose-dependent, which reduces the risk of hypoglycemia when used without insulin or sulfonylureas. The primary mechanisms include:
- Glucose-Dependent Insulin Secretion: It enhances insulin secretion from pancreatic beta-cells in response to elevated blood glucose levels. This action diminishes as glucose levels approach normal.
- Suppression of Glucagon Secretion: It inhibits the release of glucagon from pancreatic alpha-cells post-meal, reducing hepatic glucose production.
- Slowed Gastric Emptying: By delaying gastric emptying, it promotes a feeling of fullness (satiety) and leads to a slower, more controlled absorption of glucose from the gut.
- Central Appetite Suppression: Liraglutide acts on receptors in the hypothalamus, increasing satiety and reducing calorie intake, which underlies its weight-loss effect.
This multi-target approach addresses the “ominous octet” of T2DM pathophysiology, making it a highly effective therapeutic strategy.
4. Indications for Use: What is Victoza Effective For?
LSI Keywords: indications for Victoza, for type 2 diabetes, for glycemic control, for weight management, cardiovascular risk reduction.
Victoza is approved for specific, evidence-based uses.
Victoza for Glycemic Control in Type 2 Diabetes
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with T2DM. It can be used as monotherapy or, more commonly, in combination with other glucose-lowering agents like metformin, SGLT2 inhibitors, or basal insulin.
Victoza for Reduction of Major Cardiovascular Events
Based on the landmark LEADER trial, Victoza is indicated to reduce the risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — in adults with T2DM and established cardiovascular disease.
Victoza for Chronic Weight Management (Saxenda)
It is critical to note that at a higher dose (3.0 mg daily), liraglutide is marketed under the brand name Saxenda. This formulation is specifically approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
5. Instructions for Use: Dosage and Administration
LSI Keywords: instructions for use Victoza, dosage liraglutide, how to inject Victoza, titration schedule, side effects management.
Victoza is initiated at a low dose to mitigate gastrointestinal side effects. It is injected subcutaneously in the abdomen, thigh, or upper arm, once daily at any time, independent of meals.
Standard Titration Schedule for T2DM:
| Week | Dosage | Purpose |
|---|---|---|
| Week 1 | 0.6 mg once daily | Initiating dose to reduce GI symptoms |
| Week 2 | 1.2 mg once daily | Therapeutic dose for many patients |
| Week 3+ | 1.8 mg once daily | Maximum therapeutic dose if needed |
The dose should not be increased if the 1.2 mg dose is not tolerated. For the cardiovascular risk reduction indication, the target dose is 1.8 mg daily. Patients must be trained on proper injection technique, site rotation, and needle disposal.
6. Contraindications and Drug Interactions of Victoza
LSI Keywords: contraindications for Victoza, side effects liraglutide, interactions with other drugs, pancreatitis risk, thyroid C-cell tumor warning.
Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- History of serious hypersensitivity reaction to liraglutide or any product component.
Warnings and Precautions:
- Risk of Thyroid C-Cell Tumors: Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents. Human relevance is uncertain, but it is contraindicated in patients at high risk.
- Pancreatitis: Has been reported; discontinue permanently if pancreatitis is suspected.
- Hypoglycemia: Risk increases when used with insulin or insulin secretagogues (e.g., sulfonylureas). Dose reduction of these agents may be needed.
- Acute Kidney Injury: Monitor renal function in patients reporting severe GI reactions (nausea, vomiting, diarrhea) leading to dehydration.
- Diabetic Retinopathy: Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.
Common Side Effects: Nausea, diarrhea, vomiting, constipation, dyspepsia. These are usually transient and dose-dependent.
Drug Interactions: The primary interaction is the increased risk of hypoglycemia with insulin and sulfonylureas, necessitating dose adjustment. Liraglutide delays gastric emptying, which may impact the absorption rate of orally administered drugs (e.g., antibiotics, oral contraceptives). Counsel patients to take such drugs at least 1 hour before or 4 hours after Victoza.
7. Clinical Studies and Evidence Base for Victoza
LSI Keywords: clinical studies Victoza, LEADER trial, scientific evidence liraglutide, cardiovascular outcomes, glycemic efficacy.
The evidence for Victoza is robust, anchored by the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results) trial. This multicenter, double-blind, placebo-controlled study followed over 9,300 adults with T2DM and high cardiovascular risk for a median of 3.8 years.
- Primary Outcome: Victoza demonstrated a 13% relative risk reduction in 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke) vs. placebo (p=0.01 for superiority).
- Key Secondary Outcomes: A 22% relative risk reduction in cardiovascular mortality and a 15% reduction in all-cause mortality.
- Glycemic & Weight Data: As expected, it showed superior HbA1c reduction (~0.4% difference) and weight loss (~2.3 kg difference) versus placebo.
This trial, published in The New England Journal of Medicine, provided the definitive evidence that shifted Victoza from a purely glycemic agent to a cardioprotective one. Earlier phase 3 trials (the LEAD program) established its efficacy in HbA1c reduction (typically 1.0-1.5% from baseline) and weight loss (2-3 kg on average).
8. Comparing Victoza with Similar GLP-1 Agonists and Choosing Therapy
LSI Keywords: Victoza vs Ozempic, GLP-1 agonists comparison, daily vs weekly injection, choosing a GLP-1.
Choosing among GLP-1 receptor agonists involves considering pharmacokinetics, dosing frequency, evidence, and patient preference.
| Feature | Victoza (liraglutide) | Ozempic (semaglutide) injection | Trulicity (dulaglutide) |
|---|---|---|---|
| Dosing Frequency | Once daily | Once weekly | Once weekly |
| CV Outcome Trial | LEADER (CV benefit) | SUSTAIN-6 (CV benefit) | REWIND (CV benefit) |
| Avg. HbA1c Reduction | ~1.0 - 1.5% | ~1.5 - 1.8% | ~1.0 - 1.5% |
| Avg. Weight Loss | ~2-3 kg | ~4-5 kg | ~1-3 kg |
| Key Consideration | Proven mortality benefit; daily injection | Potentially superior efficacy; weekly injection | Convenient weekly pen; strong REWIND data |
The choice is individualized. Victoza’s daily regimen may be less convenient but allows for more flexible dosing. Its strongest card is the mortality benefit shown in LEADER. For a patient with established CVD where this is the paramount goal, Victoza remains a top-tier choice.
9. Frequently Asked Questions (FAQ) about Victoza
What is the main advantage of Victoza over older diabetes drugs?
Beyond lowering blood sugar, its main proven advantages are weight loss and, most importantly, reduction in cardiovascular events and cardiovascular death in high-risk patients, as shown in the LEADER trial.
Can Victoza be used in patients with type 1 diabetes?
No. Victoza is not approved for type 1 diabetes. Its mechanism is dependent on functioning pancreatic beta-cells.
How should I manage the common nausea with Victoza?
Start at the 0.6 mg dose for at least one week. Inject at a consistent time of day. Eat smaller, blander meals. The nausea typically subsides within a few days to weeks. Do not increase the dose until it is tolerable.
Is there a risk of hypoglycemia with Victoza alone?
The risk is low when used as monotherapy or with metformin/SGLT2 inhibitors due to its glucose-dependent mechanism. The risk significantly increases when combined with insulin or sulfonylureas.
Can Victoza be used during pregnancy or breastfeeding?
There is limited data. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is unknown if liraglutide is excreted in human milk; a decision should be made to discontinue nursing or the drug.
10. Conclusion: Validity of Victoza Use in Clinical Practice
Victoza (liraglutide) represents a validated, multi-faceted therapeutic tool in the management of type 2 diabetes. Its risk-benefit profile is strongly positive, particularly for the patient with established cardiovascular disease, where its mortality benefit is a decisive factor. While newer agents with weekly dosing and potentially greater glycemic/weight efficacy exist, Victoza’s foundation of robust, long-term cardiovascular outcomes data ensures its continued relevance. Treatment must be individualized, considering patient preferences, comorbidities, and specific therapeutic goals, always within the context of comprehensive lifestyle management.
Personal Anecdote & Clinical Experience:
You know, when Victoza first hit the scene, our endo group was split. The diabetes educators loved the weight loss angle, but some of the old guard cardiologists were skeptical—“Just another injectable sugar toy,” I remember one saying. The pancreatitis warnings in the early literature made us all a bit jumpy. I had a case early on, a 58-year-old guy, Mark, with an HbA1c of 9.2% on metformin and gliclazide, post-MI, BMI of 34. He was desperate. We started him on Victoza, and the first month was rough. He called twice a week about the nausea. My partner wanted to pull him off it, said he wasn’t a candidate. But the nurse, Sarah, she worked with him on tiny meals, timing his dose at night. We dropped the gliclazide dose preemptively.
By month three, the transformation wasn’t just in his numbers—his HbA1c was down to 7.1%—but in his demeanor. He’d lost 6 kg without “dieting,” he said, just because he wasn’t constantly hungry. He called it “quieting the food noise.” That phrase stuck with me. It wasn’t in any trial endpoint, but it was the key to his adherence. Five years later, he’s had no further CV events. His renal function, which was starting to dip, stabilized. The unexpected finding for me wasn’t in the labs; it was seeing how the GI side effects, if managed supportively, became a tolerable trade-off for patients who finally felt in control of their appetite for the first time.
We’ve since moved many patients to weekly agents for convenience, sure. But for my high-risk CV patients like Mark, where the LEADER data is etched in my mind, I still find myself reaching for liraglutide. It’s the one where I can look them in the eye and say, “This drug has been proven to help people like you live longer.” That’s a conversation that never gets old. The development struggle was real—getting past the thyroid tumor scare, managing the GI issues—but seeing the longitudinal follow-up in real practice, the sustained weight loss, the avoided events… that’s the evidence that complements the trial data. You learn that the “best” drug isn’t always the one with the biggest HbA1c drop on a chart, but the one the patient can live with—and live longer on.
More info:
Popular Products
Abana: Cardioprotective and Lipid-Management Support - An Evidence-Based Review
Product Description Abana is a well-established, polyherbal Ayurvedic formulation primarily indicated for the support of cardiovascular health. It is classified as a dietary supplement or, in some regulatory frameworks, a traditional herbal medicinal product. The formulation is based on the principles of Ayurveda, aiming to promote healthy lipid metabolism, provide antioxidant support to cardiac tissue, and maintain healthy circulation and blood pressure within normal ranges. Its name is derived from Sanskrit, meaning “that which provides strength and longevity to the heart.
Abana: Cardiovascular and Metabolic Support - An Evidence-Based Clinical Review
Product Description Abana is a well-established, polyherbal Ayurvedic formulation primarily indicated for cardiovascular support. It’s classified as a dietary supplement or, in some regions like India, as an Ayurvedic proprietary medicine. The name “Abana” itself is derived from Sanskrit, suggesting its role in promoting vitality and strength, particularly for the heart (“Hridaya” in Ayurvedic terms). For decades, it’s been a cornerstone in the management of functional cardiovascular complaints, dyslipidemia, and as a supportive therapy in hypertension, often used as an adjunct to conventional treatments.
Accupril : Contrôle Tensionnel et Protection Cardiovasculaire - Revue des Données Probantes
Product Description: Accupril est un inhibiteur de l’enzyme de conversion de l’angiotensine (IECA) bien établi, dont le principe actif est le quinapril. Il est utilisé en monothérapie ou en association pour le traitement de l’hypertension artérielle et de l’insuffisance cardiaque. Ce monographie se concentre sur son utilisation factuelle dans la pratique clinique moderne, au-delà de la simple notice officielle. 1. Introduction : Qu’est-ce que l’Accupril ? Son Rôle en Médecine Moderne L’Accupril, dont la dénomination commune internationale (DCI) est le quinapril, appartient à la classe thérapeutique des inhibiteurs de l’enzyme de conversion de l’angiotensine (IECA).
Actoplus Met: Dual-Action Glycemic Control for Type 2 Diabetes - Evidence-Based Review
Actoplus Met is a prescription medication combining pioglitazone and metformin for type 2 diabetes management. This comprehensive monograph details its dual mechanism of action, clinical efficacy, and practical use guidelines for healthcare professionals. Learn about the evidence-based indications, safety profile, and how it compares to other therapies for optimized glycemic control. Let’s cut to the chase. When a patient walks into your office with an HbA1c that’s stubbornly sitting at 8.
Aldactone
Let’s talk about Aldactone. If you’ve been in practice for a while, you remember when it was just that weird diuretic that could cause gynecomastia and hyperkalemia, tucked away on the formulary for maybe the odd case of ascites. The journey of this drug from a niche agent to a cornerstone in heart failure and resistant hypertension is one of the more fascinating stories in pharmacotherapy, born out of both serendipity and rigorous science.
Aldactone: Potassium-Sparing Diuretic for Hypertension and Hormonal Disorders - Evidence-Based Review
Product Description Aldactone, known generically as spironolactone, is a potassium-sparing diuretic and a specific antagonist of aldosterone. It’s not a dietary supplement or a typical over-the-counter medical device; it is a potent prescription medication belonging to the class of drugs known as aldosterone receptor antagonists. Its primary mechanism involves competitive binding to mineralocorticoid receptors in the distal convoluted tubules of the nephron, blocking the sodium-retaining and potassium-excreting effects of aldosterone. This results in increased excretion of sodium and water, while conserving potassium.
Alli
Alli (Orlistat 60 mg): Un Inibitore dei Lipasi per la Gestione del Peso - Revisione Basata sull’Evidenza Alli è il nome commerciale di un integratore alimentare per la gestione del peso, contenente orlistat a una dose di 60 mg per capsula. È la versione da banco (OTC) del farmaco Xenical (orlistat 120 mg), disponibile solo su prescrizione medica. Appartiene alla categoria degli inibitori delle lipasi gastrointestinali e rappresenta uno dei pochi prodotti per la perdita di peso con un meccanismo d’azione ben definito e supportato da un ampio corpus di studi clinici.
Amaryl: Effective Glycemic Control for Type 2 Diabetes - Evidence-Based Review
Product Description Amaryl, known generically as glimepiride, is a modern sulfonylurea oral antihyperglycemic agent. It is classified as a third-generation sulfonylurea and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Unlike older sulfonylureas, glimepiride demonstrates a more pancreas-selective action with potentially lower cardiovascular risk and a once-daily dosing regimen that enhances patient adherence. It works primarily by stimulating the release of insulin from functional pancreatic beta cells.
Arjuna
Let me tell you about Arjuna. It’s not just another herbal supplement on the shelf; in my two decades of practicing integrative cardiology, it’s one of the few botanicals that consistently makes me pause and reconsider the hard line between conventional pharmacotherapy and phytomedicine. We’re talking about Terminalia arjuna, the bark of this massive, sacred tree native to the Indian subcontinent. Its history in Ayurveda stretches back millennia, primarily as a hridya—a cardiac tonic.
